news
New On-Demand Course on Reversing Cognitive Decline
Globally, 47 million people are affected by Alzheimer’s disease and related dementias, and the number is expected to double every 20 years.1 Recent news about Pfizer abandoning its drug-discovery efforts for the disease may have a discouraging effect for some,2 but Functional Medicine clinicians know that there are options outside of pharmacological treatment. A personalized, systems-biology approach to cognitive decline has demonstrated impacts on overall health.
“Functional Medicine is effecting unprecedented success in the treatment of complex chronic illnesses, including Alzheimer’s disease,” said IFM Educator Dale Bredesen, MD. “Working together as a medical community, and continuing to optimize our approach to the prevention and reversal of cognitive decline, we can slash the global burden of dementia.”
Functional Medicine is effecting unprecedented success in the treatment of complex chronic illnesses, including Alzheimer’s disease.
Click to tweet
Using a Functional Medicine approach, clinicians can assess patients for mild cognitive decline and early Alzheimer’s, stratify them based on the likely causes of their dysfunction, and apply a multimodal protocol to individualize treatments for each patient that address the appropriate underlying causes. In this way, clinicians can arrest cognitive decline and, in many cases, even reverse it.
Dr. Bredesen is one of the clinician researchers whose multimodal approach has yielded successful outcomes addressing the pathogenesis of Alzheimer’s disease. The on-demand format of the course allows clinicians to learn this material in a self-paced, on-demand manner as time allows.
Formerly, IFM offered an online course, Reversing Cognitive Decline, in collaboration with MPI Cognition and Dr. Bredesen.
Learn more about IFM’s Energy Advanced Practice Module
References
- Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. London: Alzheimer’s Disease International; 2015. http://www.alz.co.uk/research/world-report-2015. Accessed March 2, 2018.
- Dilts E. Pfizer ends research for new Alzheimer’s, Parkinson’s drugs. Reuters. January 7, 2018. https://www.reuters.com/article/us-pfizer-alzheimers/pfizer-ends-research-for-new-alzheimers-parkinsons-drugs-idUSKBN1EW0TN. Accessed March 2, 2018.
